PL2173376T3 - Multimeryczne wieloepitopowe szczepionki przeciwko grypie - Google Patents

Multimeryczne wieloepitopowe szczepionki przeciwko grypie

Info

Publication number
PL2173376T3
PL2173376T3 PL08789738T PL08789738T PL2173376T3 PL 2173376 T3 PL2173376 T3 PL 2173376T3 PL 08789738 T PL08789738 T PL 08789738T PL 08789738 T PL08789738 T PL 08789738T PL 2173376 T3 PL2173376 T3 PL 2173376T3
Authority
PL
Poland
Prior art keywords
influenza vaccines
multimeric multiepitope
multiepitope influenza
multimeric
vaccines
Prior art date
Application number
PL08789738T
Other languages
English (en)
Polish (pl)
Inventor
Tamar Ben-Yedidia
Yossi Singer
Original Assignee
Biondvax Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biondvax Pharmaceuticals Ltd filed Critical Biondvax Pharmaceuticals Ltd
Publication of PL2173376T3 publication Critical patent/PL2173376T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL08789738T 2007-08-02 2008-08-03 Multimeryczne wieloepitopowe szczepionki przeciwko grypie PL2173376T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95349807P 2007-08-02 2007-08-02
EP08789738.5A EP2173376B1 (en) 2007-08-02 2008-08-03 Multimeric multiepitope influenza vaccines
PCT/IL2008/001062 WO2009016639A2 (en) 2007-08-02 2008-08-03 Multimeric multiepitope influenza vaccines

Publications (1)

Publication Number Publication Date
PL2173376T3 true PL2173376T3 (pl) 2015-08-31

Family

ID=40305020

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08789738T PL2173376T3 (pl) 2007-08-02 2008-08-03 Multimeryczne wieloepitopowe szczepionki przeciwko grypie

Country Status (17)

Country Link
US (2) US8747861B2 (enExample)
EP (1) EP2173376B1 (enExample)
JP (1) JP5654345B2 (enExample)
KR (1) KR101580660B1 (enExample)
CN (1) CN101795709B (enExample)
AU (1) AU2008281384C1 (enExample)
BR (1) BRPI0815008B8 (enExample)
CA (1) CA2695399C (enExample)
DK (1) DK2173376T3 (enExample)
EA (1) EA017887B1 (enExample)
ES (1) ES2539818T3 (enExample)
HR (1) HRP20150479T1 (enExample)
HU (1) HUE025149T2 (enExample)
MX (1) MX2010001284A (enExample)
PL (1) PL2173376T3 (enExample)
PT (1) PT2173376E (enExample)
WO (1) WO2009016639A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006206647C1 (en) 2005-01-19 2011-01-20 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
AU2008293504B2 (en) 2007-08-27 2012-04-12 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
ES2594102T3 (es) 2008-04-18 2016-12-15 Vaxinnate Corporation Mutantes por deleción de la flagelina y métodos para su uso
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
US9408873B2 (en) 2010-08-23 2016-08-09 Kang Stem Biotech Co., Ltd. Pharmaceutical composition comprising stem cells treated with NOD2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases
WO2012115715A2 (en) * 2011-02-21 2012-08-30 Vaxinnate Corporation Compositions with enhanced immunogenicity and/or reduced reactogenicity and methods of use
CA2828068C (en) * 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
BR112013032723A2 (pt) * 2011-06-20 2017-01-31 Univ Pittsburgh Commonwealth Sys Higher Education antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
ES2490915B1 (es) * 2011-09-12 2015-09-17 Laboratorios Del Dr. Esteve, S.A. Método para monitorizar las respuestas de linfocitos T citotóxicos (LTC) mediante una reacción de hipersensibilidad de tipo retardado usando epítopos de LTC definidos
CA2863083C (en) * 2012-01-26 2023-09-19 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
JP2015514097A (ja) * 2012-04-02 2015-05-18 フォリア バイオテック インコーポレイテッド 組換えパパイヤモザイクウイルスコートタンパク質およびインフルエンザワクチンにおけるその使用
CN103055311B (zh) * 2012-12-28 2014-05-21 中山大学 一种传染性喉气管炎粘膜疫苗及其制备方法和应用
AU2014204826A1 (en) * 2013-01-10 2015-07-09 Seqirus UK Limited Influenza virus immunogenic compositions and uses thereof
CA2944768C (en) 2014-04-03 2022-08-30 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
RU2769406C2 (ru) * 2016-02-03 2022-03-31 СиДжи ДИСКАВЕРИ, ИНК. Композиции гемагглютинина гриппа с гетерологичными эпитопами и/или измененными сайтами расщепления при созревании
JP2019064924A (ja) * 2016-02-24 2019-04-25 Ａｇｃ株式会社 インフルエンザワクチン
CN111148528A (zh) 2016-12-28 2020-05-12 英福瓦克思公司 流感疫苗
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
JP7382634B2 (ja) * 2017-12-21 2023-11-17 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
KR20210052389A (ko) 2018-08-27 2021-05-10 리제너론 파마슈티칼스 인코포레이티드 다운스트림 정제에서의 라만 분광법의 사용
US12239699B2 (en) 2018-09-11 2025-03-04 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
EP3986447A4 (en) * 2019-06-18 2023-08-16 Citranvi Biosciences, LLC RATIONALLY MANIPULATED CARRIER PROTEINS FOR VACCINES
CN116096404A (zh) * 2020-02-14 2023-05-09 华盛顿大学 多肽、组合物及其用于治疗或限制感染发展的用途
US11149286B1 (en) * 2020-08-17 2021-10-19 Mayo Foundation For Medical Education And Research Adenovirus vectors and methods for using adenovirus vectors
JP2023542341A (ja) * 2020-09-21 2023-10-06 エスアールアイ インターナショナル 標的化された抗原送達システム及びその使用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) * 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4643992A (en) * 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4539205A (en) * 1982-11-09 1985-09-03 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4987237A (en) * 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US5093318A (en) * 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US5011828A (en) * 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US6130082A (en) * 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
US5837268A (en) * 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
GB9201139D0 (en) 1992-01-20 1992-03-11 Connaught Lab Synthetic peptides for a rubella vaccine
IL101639A0 (en) 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
KR100278157B1 (ko) * 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
ATE214601T1 (de) * 1992-09-16 2002-04-15 Univ Tennessee Res Corp Rekombinantes vielwertiges m-protein-vakzin
US5683695A (en) * 1993-02-10 1997-11-04 United Biomedical, Inc. Production of recombinant proteins containing multiple antigenic determinants linked by flexible hinge domains
SK117395A3 (en) * 1993-03-23 1996-11-06 Smithkline Beecham Biolog Vaccine composition and manufacturing process thereof
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
US6303347B1 (en) * 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6355257B1 (en) * 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7063967B2 (en) * 1997-05-08 2006-06-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
AU732856B2 (en) * 1997-05-20 2001-05-03 Galenica Pharmaceuticals, Inc. Triterpene saponin analogs having adjuvant and immunostimulatory activity
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
DK0996717T3 (da) 1997-08-05 2006-04-10 Vlaams Interuniv Inst Biotech Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination
DE69815692T2 (de) * 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. Öl in wasser emulsionen mit saponinen
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
PT1042001E (pt) * 1997-12-16 2002-09-30 Chiron Corp Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua
GB9807805D0 (en) 1998-04-09 1998-06-10 Smithkline Beecham Biolog Vaccine
KR20010042573A (ko) 1998-04-09 2001-05-25 장 스테판느 애쥬번트 조성물
US6630161B1 (en) 1998-05-07 2003-10-07 Ribi Immunochem Research, Inc. Adjuvant composition and methods for its use
EP1105487A1 (en) * 1998-08-21 2001-06-13 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by The Secretary, Department of Health and Human Services Recombinant multivalent malarial vaccine against plasmodium falciparum
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
AU6226100A (en) 1999-07-19 2001-04-24 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
CA2386499A1 (en) 1999-10-05 2001-04-12 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
US6843781B2 (en) * 1999-10-14 2005-01-18 Becton, Dickinson And Company Intradermal needle
CA2410297C (en) 2000-06-23 2011-03-15 American Cyanamid Company Assembly of wild-type and chimeric influenza virus-like particles (vlps)
WO2004003145A2 (en) * 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
CA2516919A1 (en) 2003-03-07 2004-09-23 Merck & Co., Inc. Influenza virus vaccine
US7108679B2 (en) * 2004-03-11 2006-09-19 Becton, Dickinson And Company Intradermal syringe and needle assembly
WO2006081007A2 (en) * 2004-12-16 2006-08-03 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
NZ556004A (en) 2004-12-21 2010-05-28 Vaxinnate Corp Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein
AU2006206647C1 (en) 2005-01-19 2011-01-20 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
MX2007015105A (es) * 2005-06-01 2008-03-18 Variation Biotechnologies Inc Formulacion de vacuna de influenza a base de peptido.
US7260958B2 (en) * 2005-09-14 2007-08-28 National Taipei University Technology Electrohydrodynamic condenser device
CA2628379A1 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Adminstration routes for priming/boosting with influenza vaccines
US7914797B2 (en) * 2005-12-06 2011-03-29 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Influenza vaccine
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
EP2069376A4 (en) * 2006-07-21 2013-10-16 Pharmexa Inc INDUCTION OF CELLULAR IMMUNE RESPONSES TO INFLUENZA VIRUS BY COMPOSITIONS OF PEPTIDES AND NUCLEIC ACIDS
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
KR20100075843A (ko) 2007-08-21 2010-07-05 다이나박스 테크놀로지 코퍼레이션 인플루엔자 단백질 조성물 및 그 제조 및 사용 방법

Also Published As

Publication number Publication date
JP2010535026A (ja) 2010-11-18
DK2173376T3 (en) 2015-06-29
EP2173376A2 (en) 2010-04-14
KR20100045473A (ko) 2010-05-03
AU2008281384B2 (en) 2012-02-16
ES2539818T3 (es) 2015-07-06
HRP20150479T1 (hr) 2015-07-17
PT2173376E (pt) 2015-07-30
HUE025149T2 (hu) 2016-01-28
BRPI0815008B8 (pt) 2021-05-25
WO2009016639A2 (en) 2009-02-05
KR101580660B1 (ko) 2015-12-28
CA2695399A1 (en) 2009-02-05
HK1142809A1 (en) 2010-12-17
US9353159B2 (en) 2016-05-31
US20140286982A1 (en) 2014-09-25
CN101795709B (zh) 2013-07-17
EP2173376B1 (en) 2015-03-25
US20110182974A1 (en) 2011-07-28
MX2010001284A (es) 2010-08-31
US8747861B2 (en) 2014-06-10
AU2008281384C1 (en) 2012-08-16
CN101795709A (zh) 2010-08-04
WO2009016639A3 (en) 2009-04-30
EA017887B1 (ru) 2013-03-29
JP5654345B2 (ja) 2015-01-14
BRPI0815008B1 (pt) 2019-11-19
EA201070219A1 (ru) 2010-08-30
CA2695399C (en) 2017-10-17
AU2008281384A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
PT2173376E (pt) Vacinas de influenza multiepitópicas multiméricas
SI2185191T1 (sl) Cepiva proti influenci z majhnimi dodatki
IL196024A0 (en) Influenza vaccine
IL199663A0 (en) Vaccine
IL211184A0 (en) Polyvalent vaccine
IL201782A0 (en) Vaccine
GB0717911D0 (en) Vaccine
GB0711858D0 (en) Vaccine
PL2358386T3 (pl) Zoptymalizowane szczepionki na grypę
ZA201004303B (en) Vaccine
AP2010005166A0 (en) Vaccines
EP1998814A4 (en) NEW VACCINES AGAINST INFLUENZA M2
SI2043682T1 (sl) Influenčno cepivo
ZA201100962B (en) Influenza vaccines
GB0700135D0 (en) Vaccine
GB0710538D0 (en) Vaccine
ZA201003851B (en) Vaccine
ZA200900062B (en) Influenza vaccine
GB0623865D0 (en) Influenza vaccine
GB0618195D0 (en) Influenza vaccine
GB0619090D0 (en) Influenza vaccine
GB0623218D0 (en) Influenza vaccine
GB0625453D0 (en) Influenza vaccine
GB0721928D0 (en) Vaccine
GB0713188D0 (en) Vaccine